Cargando…
Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer
Immune checkpoint inhibitors (ICIs) treatment is becoming a new hope for cancer treatment. However, most prostate cancer (PCa) patients do not benefit from it. In order to achieve the accuracy of ICIs treatment in PCa and reduce unnecessary costs for patients, we have analyzed the data from TCGA dat...
Autores principales: | Gao, Ze, Tao, Yiran, Lai, Yiming, Wang, Qiong, Li, Zean, Peng, Shirong, Chen, Junxiu, Cai, Wenli, Li, Kaiwen, Huang, Hai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423880/ https://www.ncbi.nlm.nih.gov/pubmed/32850758 http://dx.doi.org/10.3389/fbioe.2020.00930 |
Ejemplares similares
-
Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway
por: Li, Kaiwen, et al.
Publicado: (2020) -
The metastatic promoter DEPDC1B induces epithelial‐mesenchymal transition and promotes prostate cancer cell proliferation via Rac1‐PAK1 signaling
por: Li, Zean, et al.
Publicado: (2020) -
SYTL2 promotes metastasis of prostate cancer cells by enhancing FSCN1-mediated pseudopodia formation and invasion
por: Li, Zean, et al.
Publicado: (2023) -
Combination of immune checkpoint blockade and targeted gene regulation of angiogenesis for facilitating antitumor immunotherapy
por: Zhan, Jing, et al.
Publicado: (2023) -
Immune Signatures Combined With BRCA1-Associated Protein 1 Mutations Predict Prognosis and Immunotherapy Efficacy in Clear Cell Renal Cell Carcinoma
por: Gao, Ze, et al.
Publicado: (2021)